Documenting biospecimen conditions in reports of studies

JAMA

Volumn 300, Issue 6, 2008, Pages 650-651

  Robb, James A ^a   Moore, Helen M ^a   Compton, Carolyn C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOMATERIAL; BIOSPECIMEN; RNA; TUMOR MARKER;

LABORATORY DIAGNOSIS; LETTER; MEDICAL INFORMATION; MOLECULAR BIOLOGY; ORGAN PRESERVATION; PRIORITY JOURNAL; REPRODUCIBILITY; VALIDATION STUDY; DIAGNOSTIC PROCEDURE; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETICS; HEALTH CARE FACILITY; HUMAN; NEOPLASM; NOTE; PATHOLOGY;

BIOLOGICAL SPECIMEN BANKS; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 49249108600     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.6.650-c     Document Type: Letter

References (5)

1. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.
2. Advancing cancer research through biospecimen science: March 13-14, 2008. National Cancer Institute Web site. http://brnsymposium.com/meeting/ brnsymposium/2008/agenda.asp. Accessed May 29, 2008.
3. Gene Expression Omnibus (GEO). National Center for Biotechnology Information Web site. http://www.ncbi.nlm.nih.gov/geo/. Accessed May 29, 2008.
4. McShane LM, Altman DG, Sauerbrei W. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
5. National Cancer Institute best practices for biospecimen resources: June 2007. http://biospecimens.cancer.gov/global/pdfs/NCI_Best_Practices_060507.pdf. Accessed May 29, 2008.